Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment
- PMID: 29417338
- DOI: 10.1007/s11010-018-3294-z
Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment
Abstract
Cancer remains a global health problem and approximately 1.7 million new cancer cases are diagnosed every year worldwide. Although diverse molecules are currently being explored as targets for cancer therapy the tumor treatment and therapy is highly tricky. Secondary messengers are important for hormone-mediated signaling pathway. Cyclic AMP (cAMP), a secondary messenger responsible for various physiological processes regulates cell metabolism by activating Protein kinase A (PKA) and by targeting exchange protein directly activated by cAMP (EPAC). EPAC is present in two isoforms EPAC1 and EPAC2, which exhibit different tissue distribution and is involved in GDP/GTP exchange along with activating Rap1- and Rap2-mediated signaling pathways. EPAC is also known for its dual role in cancer as pro- and anti-proliferative in addition to metastasis. Results after perturbing EPAC activity suggests its involvement in cancer cell migration, proliferation, and cytoskeleton remodeling which makes it a potential therapeutic target for cancer treatments.
Keywords: Brain cancer; Breast cancer therapy; EPAC; Leukemia; Melanoma; Metastasis; Ovarian cancer; cAMP signaling.
Similar articles
-
Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor.J Cell Biol. 2003 Feb 17;160(4):487-93. doi: 10.1083/jcb.200209105. Epub 2003 Feb 10. J Cell Biol. 2003. PMID: 12578910 Free PMC article.
-
Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis.Mol Cell Biochem. 2017 Jun;430(1-2):115-125. doi: 10.1007/s11010-017-2959-3. Epub 2017 Feb 16. Mol Cell Biochem. 2017. PMID: 28210903
-
EPAC activation inhibits acetaldehyde-induced activation and proliferation of hepatic stellate cell via Rap1.Can J Physiol Pharmacol. 2016 May;94(5):498-507. doi: 10.1139/cjpp-2015-0437. Epub 2015 Nov 19. Can J Physiol Pharmacol. 2016. PMID: 26854595
-
The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention.Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):75-81. doi: 10.1093/abbs/gmv115. Epub 2015 Nov 2. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26525949 Free PMC article. Review.
-
Epac: new emerging cAMP-binding protein.BMB Rep. 2021 Mar;54(3):149-156. doi: 10.5483/BMBRep.2021.54.3.233. BMB Rep. 2021. PMID: 33298248 Free PMC article. Review.
Cited by
-
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment.J Hematol Oncol. 2024 Jan 17;17(1):5. doi: 10.1186/s13045-024-01524-x. J Hematol Oncol. 2024. PMID: 38233872 Free PMC article. Review.
-
Epac: A Promising Therapeutic Target for Vascular Diseases: A Review.Front Pharmacol. 2022 Jul 14;13:929152. doi: 10.3389/fphar.2022.929152. eCollection 2022. Front Pharmacol. 2022. PMID: 35910387 Free PMC article. Review.
-
Phospho-substrate profiling of Epac-dependent protein kinase C activity.Mol Cell Biochem. 2019 Jun;456(1-2):167-178. doi: 10.1007/s11010-019-03502-1. Epub 2019 Feb 9. Mol Cell Biochem. 2019. PMID: 30739223 Free PMC article.
-
EPAC2: A new and promising protein for glioma pathogenesis and therapy.Oncol Rev. 2020 Apr 30;14(1):446. doi: 10.4081/oncol.2020.446. eCollection 2020 Feb 18. Oncol Rev. 2020. PMID: 32395202 Free PMC article.
-
Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization.Cell Cycle. 2024 Mar;23(6):682-692. doi: 10.1080/15384101.2024.2355825. Epub 2024 May 24. Cell Cycle. 2024. PMID: 38794797
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
